Comparison of the human gastric microbiota in hypochlorhydric states arising as a result of Helicobacter pylori-induced atrophic gastritis, autoimmune atrophic gastritis and proton pump inhibitor use
Open accessPublished version of a preprint
Abstract
ABSTRACT Objective Several conditions associated with reduced gastric acid secretion confer an altered risk of developing a gastric malignancy. Helicobacter pylori -induced atrophic gastritis predisposes to gastric adenocarcinoma, autoimmune atrophic gastritis is a precursor of type I gastric neuroendocrine tumours, whereas proton pump inhibitor (PPI) use does not affect stomach cancer risk. We hypothesised that each of these conditions was associated with specific alterations in the gastric microbiota and that this influenced subsequent tumour risk. Design 95 patients (in groups representing normal stomach, PPI treated, H. pylori gastritis, H. pylori -induced atrophic gastritis and autoimmune atrophic gastritis) were selected from a cohort of 1400. RNA extracted from gastric corpus biopsies was analysed using 16S rRNA sequencing (MiSeq). Results Samples from normal stomachs and patients treated with PPIs demonstrated similarly high microbial diversity. Patients with autoimmune atrophic gastritis also exhibited relatively high microbial diversity, but with samples dominated by Streptococcus. H. pylori colonisation was associated with decreased microbial diversity and reduced complexity of co-occurrence networks. H. pylori -induced atrophic gastritis resulted in lower bacterial abundances and diversity, whereas autoimmune atrophic gastritis resulted in greater bacterial abundance and equally high diversity compared to normal stomachs. Pathway analysis suggested that glucose-6-phospahte1-dehydrogenase and D-lactate dehydrogenase were over represented in H. pylori -induced atrophic gastritis versus autoimmune atrophic gastritis, and that both these groups showed increases in fumarate reductase. Conclusion Autoimmune and H. pylori -induced atrophic gastritis were associated with different gastric microbial profiles. PPI treated patients showed relatively few alterations in the gastric microbiota compared to healthy subjects. SIGNIFICANCE OF THIS STUDY 1. What is already known about this subject? Some conditions which result in reduced gastric acid secretion and hypochlorhydria are associated with an increased risk of gastric tumourigenesis. This risk is different in patients with H. pylori -induced atrophic gastritis, autoimmune atrophic gastritis and chronic proton pump inhibitor use. Hypochlorhydria and H. pylori infection cause alterations in the composition of the gastric microbiota. 2. What are the new findings? We used 16S rRNA sequencing to characterise the microbiota in gastric corpus biopsies from a well characterised cohort of patients. The gastric microbiota was different in patients who were hypochlorhydric as a result of H. pylori -induced atrophic gastritis, autoimmune atrophic gastritis and proton pump inhibitor use. Biochemical pathways associated with gastric carcinogenesis such as the fumarate reductase pathway were predicted to be altered in patients with atrophic gastritis. 3. How might it impact on clinical practice in the foreseeable future? Understanding how the microbiota that colonise the hypochlorhydric stomach influence gastric carcinogenesis may ultimately permit stratification of patients’ subsequent tumour risk. Interventions that alter the composition of the gastric microbiome in hypochlorhydric patients with atrophic gastritis should be tested to investigate whether they alter the subsequent risk of developing gastric malignancy.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Streptococcaceae are the most abundant family observed during PPI therapy, followed by Prevotellaceae, Campylobacteraceae and Leptotrichiaceae.
“Streptococcaceae are the most abundant family observed during PPI therapy, followed by Prevotellaceae, Campylobacteraceae and Leptotrichiaceae[58].”
From Proton pump inhibitors and dysbiosis: current knowledge and aspects to be clarified (2019) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Classification and Grading of Gastritis: The Updated Sydney System
Dixon, M. F., Genta, R. M., Yardley, J. H., & Correa, P. (1996) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199610000-00001 · Cited by 5,185 · see citing works
Helicobacter pylori Infection and the Development of Gastric Cancer
Uemura, N., Okamoto, S., Yamamoto, S., Matsumura, N., Yamaguchi, S., Yamakido, M., Taniyama, K., Sasaki, N., & Schlemper, R. J. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa001999 · Cited by 4,466 · see citing works
Reagent and laboratory contamination can critically impact sequence-based microbiome analyses
Salter, S. J., Cox, M. J., Turek, E. M., Calus, S. T., Cookson, W. O., Moffatt, M. F., Turner, P., Parkhill, J., Loman, N. J., & Walker, A. W. (2014) · BMC Biology · doi:10.1186/s12915-014-0087-z · Cited by 3,463 · see citing works
Correa, P. (1992) · PubMed · Cited by 3,149 · see citing works
Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach
Manichanh, C., Rigottier-Gois, L., Bonnaud, E., Gloux, K., Pelletier, E., Frangeul, L., Nalin, R., Jarrin, C., Chardon, P., Marteau, P., et al. (2006) · Gut · doi:10.1136/gut.2005.073817 · Cited by 2,277 · see citing works
Molecular analysis of the bacterial microbiota in the human stomach
Bik, E. M., Eckburg, P. B., Gill, S. R., Nelson, K. E., Purdom, E. A., François, F., Perez-Perez, G., Blaser, M. J., & Relman, D. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506655103 · Cited by 1,160 · see citing works
Commensal bacteria at the interface of host metabolism and the immune system
Brestoff, J. R., & Artis, D. (2013) · Nature Immunology · doi:10.1038/ni.2640 · Cited by 945 · see citing works
Proton pump inhibitors alter the composition of the gut microbiota
Jackson, M. A., Goodrich, J. K., Maxan, M.-E., Freedberg, D. E., Abrams, J. A., Poole, A. C., Sutter, J. L., Welter, D., Ley, R. E., Bell, J. T., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310861 · Cited by 895 · see citing works
Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer
Farrell, J. J., Zhang, L., Zhou, H., Chia, D., Elashoff, D., Akin, D., Paster, B. J., Joshipura, K., & Wong, D. T. W. (2012) · Gut · doi:10.1136/gutjnl-2011-300784 · Cited by 662 · see citing works
Microbiota disbiosis is associated with colorectal cancer
Gao, Z., Guo, B., Gao, R., Zhu, Q., & Qin, H. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00020 · Cited by 537 · see citing works
Structure of fumarate reductase from Wolinella succinogenes at 2.2 Å resolution
Lancaster, C. R. D., Kröger, A., Auer, M., & Michel, H. (1999) · Nature · doi:10.1038/46483 · Cited by 339 · see citing works
Eun, C. S., Kim, B. K., Han, D. S., Kim, S., Kim, K. M., Choi, B. Y., Song, K. S., Kim, Y. S., & Kim, J. F. (2014) · Helicobacter · doi:10.1111/hel.12145 · Cited by 292 · see citing works
Biarc, J. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh091 · Cited by 240 · see citing works
Systematic review: gastric cancer incidence in pernicious anaemia
Vannella, L., Lahner, E., Osborn, J., & Annibale, B. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12177 · Cited by 235 · see citing works
Microbial Communities of the Upper Respiratory Tract and Otitis Media in Children
Laufer, A. S., Metlay, J. P., Gent, J. F., Fennie, K. P., Kong, Y., & Pettigrew, M. M. (2011) · mBio · doi:10.1128/mbio.00245-10 · Cited by 224 · see citing works
Schulz, C., Schütte, K., Koch, N., Vilchez‐Vargas, R., Wos‐Oxley, M. L., Oxley, A. P. A., Vital, M., Malfertheiner, P., & Pieper, D. H. (2016) · Gut · doi:10.1136/gutjnl-2016-312904 · Cited by 221 · see citing works
Keszei, A. P., Goldbohm, R. A., Schouten, L. J., Jakszyn, P. G., & van den Brandt, P. A. (2012) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.112.043885 · Cited by 198 · see citing works
Li, T. H., Qin, Y., Sham, P. C., Lau, K. S., Chu, K., & Leung, W. K. (2017) · Scientific Reports · doi:10.1038/srep44935 · Cited by 180 · see citing works
Review article: pathogenesis and management of gastric carcinoid tumours
Burkitt, M. D., & Pritchard, D. M. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03130.x · Cited by 177 · see citing works
Self-citationvon Rosenvinge, E. C., Song, Y., White, J. R., Maddox, C., Blanchard, T. G., & Fricke, W. F. (2013) · The ISME Journal · doi:10.1038/ismej.2013.33 · Cited by 153 · see citing works
Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions
Song, H., Zhu, J., & Lu, D. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010623.pub2 · Cited by 132 · see citing works
Coccoid Forms ofHelicobacter pyloriin the Human Stomach
Chan, W.-Y., Hui, P., Leung, K.-M., et al. (1994) · American Journal of Clinical Pathology · doi:10.1093/ajcp/102.4.503 · Cited by 128 · see citing works
Overexpression of G6PD is associated with poor clinical outcome in gastric cancer
Wang, J., 袁伟杰, Chen, Z., Wu, S., 陈晋湘, Ge, J., Hou, F., & Chen, Z. (2011) · Tumor Biology · doi:10.1007/s13277-011-0251-9 · Cited by 126 · see citing works
Effects of Proton Pump Inhibitors on the Gastric Mucosa-Associated Microbiota in Dyspeptic Patients
Paroni Sterbini, F., Palladini, A., Masucci, L., Cannistraci, C. V., Pastorino, R., Ianiro, G., Bugli, F., Martini, C., Ricciardi, W., Gasbarrini, A., et al. (2016) · Applied and Environmental Microbiology · doi:10.1128/aem.01437-16 · Cited by 108 · see citing works
Ziebarth, D. (1997) · Carcinogenesis · doi:10.1093/carcin/18.2.383 · Cited by 89 · see citing works
Gastric microbiota in the functional dyspepsia patients treated with probiotic yogurt
Nakae, H., Tsuda, A., Matsuoka, T., Mine, T., & Koga, Y. (2016) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2016-000109 · Cited by 87 · see citing works
Catsburg, C., Gago-Domínguez, M., Yuan, J., Castelao, J. E., Cortessis, V. K., Pike, M. C., & Stern, M. C. (2013) · International Journal of Cancer · doi:10.1002/ijc.28331 · Cited by 86 · see citing works
Boyce, M. J., Moore, A. R., Sagatun, L., Parsons, B. N., Varró, A., Campbell, F., Fossmark, R., Waldum, H. L., & Pritchard, D. M. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13146 · Cited by 67 · see citing works
Self-citationMoore, A. R., Boyce, M. J., Steele, I. A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076462 · Cited by 64 · see citing works
Self-citationSuccinate dehydrogenase-deficient gastrointestinal stromal tumors
Wang, Y. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i8.2303 · Cited by 54 · see citing works
The Impact of Helicobacter pylori Infection on the Gastric Microbiota of the Rhesus Macaque
Martín, M. E., Bhatnagar, S., George, M. D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076375 · Cited by 49 · see citing works
Varró, A., & Ardill, J. E. S. (2003) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/000456303322326380 · Cited by 45 · see citing works
Khosravi, Y., Dièye, Y., Loke, M. F., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112214 · Cited by 44 · see citing works
Immunochemical studies on big gastrin using NH2-terminal specific antisera
Dockray, G. J. (1980) · Regulatory Peptides · doi:10.1016/0167-0115(80)90270-0 · Cited by 40 · see citing works
Kim, H. S., Lee, H. E., Yang, H., et al. (2013) · Pathobiology · doi:10.1159/000357017 · Cited by 38 · see citing works
Potential of fumarate reductase as a novel therapeutic target in Helicobacter pylori infection
Ge, Z. (2002) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.6.2.135 · Cited by 35 · see citing works
Li, N., Han, L., Chen, J., et al. (2012) · Journal of Basic Microbiology · doi:10.1002/jobm.201100370 · Cited by 31 · see citing works
Coulton, G. R., & Firth, J. A. (1983) · The Histochemical Journal · doi:10.1007/bf01003977 · Cited by 26 · see citing works
Huang, B.-R., Tsai, C.-F., Lin, H.-Y., Tseng, W., Huang, S.-S., Wu, C., Lin, C., Yeh, W., & Lu, D. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.03.004 · Cited by 26 · see citing works
Miracco, C., Pacenti, L., Santopietro, R., BIAGIOLI, M., Fimiani, M., Perotti, R., Rubegni, P., Pirtoli, L., & Luzi, P. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20001101)88:3 · Cited by 23 · see citing works
Kumar, J. D., Steele, I. A., Moore, A. R., et al. (2015) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00084.2015 · Cited by 23 · see citing works
Self-citationKassem, I. I., Khatri, M., Sanad, Y. M., Wolboldt, M., Saif, Y. Μ., Olson, J. W., & Rajashekara, G. (2014) · MicrobiologyOpen · doi:10.1002/mbo3.158 · Cited by 16 · see citing works
Boyce, M. J., Moore, A. H., Parsons, B. N., et al. (2016) · Endocrine Abstracts · doi:10.1530/endoabs.46.oc1 · Cited by 2 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Lenti, M. V., Rugge, M., Lahner, E., Miceli, E., Toh, B.-H., Genta, R. M., De Block, C., Hershko, C., & Di Sabatino, A. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0187-8 · Cited by 350 · see citing works
Proton pump inhibitors and dysbiosis: current knowledge and aspects to be clarified
Bruno, G., Zaccari, P., Rocco, G., Scalese, G., Panetta, C., Porowska, B., Pontone, S., & Severi, C. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i22.2706 · Cited by 258 · see citing works
Macke, L., Schulz, C., Koletzko, L., & Malfertheiner, P. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15604 · Cited by 118 · see citing works
Bruno, G., Rocco, G., Zaccari, P., Porowska, B., Mascellino, M. T., & Severi, C. (2018) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2018/6237239 · Cited by 32 · see citing works
- Authors
- Parsons, B. N., Ijaz, U. Z., D’Amore, R., Burkitt, M. D., Eccles, R., Lenzi, L., Duckworth, C. A., Moore, A. R., Tiszlavicz, L., Varro, A., Hall, N., & Pritchard, D. M.
- Affiliations
- University of Liverpool (GB)
- University of Glasgow (GB)
- University of East Anglia (GB)
- Corresponding author
- Pritchard, D. Mark
- ORCID
- Venue
- PLOS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-11-02
- Volume
- 13
- Issue
- 11
- Pages
- e1006653
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- PMC
- PMC5667734
- OpenAlex
- W2620581837
- Cited by
- 210
- References
- 43
- Citations by year
- 2026: 15 · 2025: 22 · 2024: 17 · 2023: 25 · 2022: 31 · 2021: 26 · 2020: 31 · 2019: 32 · 2018: 10
- FWCI
- 20.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Pathogens (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- UEA Digital Repository (University of East Anglia) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Worldwide Cancer Research (12-1028)
- Natural Environment Research Council (NE/L011956/1)
- Wellcome Trust (097826/Z/11/Z)
- Core (None)
- Topics
- Health Sciences › Medicine › Surgery › Helicobacter pylori-related gastroenterology studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- gastric microbiota, atrophic gastritis, Helicobacter pylori, autoimmune atrophic gastritis, proton pump inhibitors, hypochlorhydria, gastric cancer risk, Streptococcus, microbial diversity, co-occurrence networks, glucose-6-phosphate dehydrogenase, D-lactate dehydrogenase, fumarate reductase, gastric adenocarcinoma, gastric neuroendocrine tumor
- MeSH terms
- Gastrointestinal Microbiome, Achlorhydria, Adult, Aged, Autoimmune Diseases, England, Female, Gastric Mucosa, Gastritis, Atrophic, Hospitals, University, Humans, Male, Middle Aged, Risk, Stomach Neoplasms, Cohort Studies, Cluster Analysis, Helicobacter pylori, Helicobacter Infections, Proton Pump Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
